Board of directors-Faheem Hasnain

Faheem Hasnain

Chairman of the Board

Mr. Hasnain served as President, CEO and as a Director of Receptos, Inc. from November 2010 to August 2015.  Receptos was a public company formed in 2009, with specific focus in immunology and metabolic disorders, and was purchased by Celgene Corporation for $7.8b in August 2015.  Receptos focused in autoimmune disorders, including multiple sclerosis and inflammatory bowel disease.

Prior to joining Receptos, Mr. Hasnain was the President and Chief Executive Officer and a director of Facet Biotech Corporation, a biology-driven antibody company with a focus in multiple sclerosis and oncology. He held that position from December 2008 until the company’s acquisition by Abbott Laboratories in April 2010.

Previously, Mr. Hasnain was President, Chief Executive Officer and a Director of PDL BioPharma, Inc. from October 2008 until Facet Biotech was spun off from PDL BioPharma in December 2008. From October 2004 to September 2008, Mr. Hasnain served at Biogen Idec Inc., a biotechnology company specializing in neurological disorders, autoimmune disorders and cancer, most recently as Executive Vice President in charge of the oncology/rheumatology strategic business unit. Prior to Biogen Idec, Mr. Hasnain held roles with Bristol-Myers Squibb, where he was President of the Oncology Therapeutics Network, and for 14 years at GlaxoSmithKline and its predecessor organizations.

Mr. Hasnain is currently chairman of Tocagen, Inc. and SENTÉ® and also serves on the board of directors of Kura Oncology, Inc. and Vital Therapies, Inc.  Prior board experiences include service on the board of directors of Ambit Biosciences Corporation, Seragon Pharmaceuticals, Somaxon Pharmaceuticals, Aragon Pharmaceuticals and, Tercica, Inc.  Mr. Hasnain is a Board Member of BIO (a lobby and policy development organization for the biotech industry).  Mr. Hasnain received a B.H.K. and B.Ed. from the University of Windsor Ontario in Canada.

Next, read about Mireille Gillings, Ph.D.